Market Trends of Global CDKL5 Deficiency Disorder (CDD) Industry
This section covers the major market trends shaping the Deficiency Disorder Market according to our research experts:
The First Line Treatment Segment is Expected to Hold a Major Market Share in the CDKL5 deficiency disorder Market
The first-line treatment segment is expected to hold a significant market share over the forecast period. Seizures are a big problem in CDKL5. The majority of affected children start having them within the first few weeks or months of life. Their pattern often changes and evolves with age. In many cases, seizure control proves difficult to maintain with conventional anti-epileptic drugs or other types of treatment.
Treatment for neurologic features of CDKL5 deficiency disorder is symptom-based and empiric rather than CDKL5 deficiency disorder-specific, though clinical trials for CDKL5 deficiency disorder are emerging. Traditional drugs are the first line of treatment for CDKL deficiency disorder. They include valproate and stiripentol. These drugs help in controlling seizures and improve cognitive function. In 2022, ganaxolone (Ztalmy) was approved to treat seizures associated with CDKL5 deficiency disorder in patients two years of age and older. This is the first treatment for seizures associated with CDKL5 deficiency disorder and the first treatment specifically for CDKL5 deficiency disorder. As per the article titled ' Current Neurologic Treatment and Emerging Therapies in CDKL5 Deficiency Disorder' published in September 2021, the most commonly used anti-seizure medications in CDD were a broad spectrum, including clobazam, valproate, topiramate, levetiracetam, and vigabatrin, and 29.6% of individuals were treated with steroids or Adrenocorticotropic hormone.
Thus the above-mentioned factors are expected to drive the growth of the studied segment during the forecast period.
North America is expected to Hold a Significant Share in the Market and is expected to do the same in the Forecast Period.
North America is expected to hold a major market share in the global CDKL5 deficiency disorder market due to the rise in the prevalence of CDKL5 deficiency disorder in this region also the increased awareness of neurological diseases. The International Foundation for CDKL5 Research has eight CDKL5 Centers of Excellence in the United States - more than any other country in the world. The centers are the driving force that establishes and maintains these Centers of Excellence. According to The Orphan Disease Center in 2021, the CDKL5 gene is present on the X chromosome; most described CDKL5 patients are females (>80%), whereas boys with CDKL5 deficiency tend to show more severe symptoms. The seizures associated with CDKL5 are largely resistant to control with current anti-epileptic drugs. Approximately 1,500 patients have been diagnosed with CDKL5 deficiency globally. The prevalence is likely higher due to mis- and un-diagnosed cases.
Moreover, the United States is the most affected country across the world, as there are higher numbers of patients suffering from CDKL5 deficiency disorder and higher in the North American region as the patient population is increasing compared to other countries. For instance, as per the report published by Loulou Foundation International Foundation for CDKL5 Research in 2020, current estimates of prevalence at one referral center in the United States suggest that CDKL5 deficiency may be found in about one in 75,000, representing less than 4,500 individuals with CDKL5 deficiency in the United States.
In addition, high expenditure on healthcare and genetic testing, especially in the United States and Canada, along with increased awareness about the disease, is fueling the growth of the overall regional Market to a large extent.
